The objectives of the work were to develop a lipid based delivery system for aspirin and to evaluate its physicochemical and pharmacodynamic properties.Aspirin-loaded solid lipid microparticles(SLMs)were formulated by...The objectives of the work were to develop a lipid based delivery system for aspirin and to evaluate its physicochemical and pharmacodynamic properties.Aspirin-loaded solid lipid microparticles(SLMs)were formulated by hot homogenization and analysed for their encapsulation efficiency(EE%),in vitro release,particle size,anti-inflammatory and ulcer inhibition properties.Particle size ranged from 33.10±5.85 to 43.50±7.27μm for batches A1 to A3 SLMs loaded with 1,3 and 5%aspirin and containing Poloxamer 407,while batches B1,B2 and B3 formulated with Soluplus as surfactant had particle size range of 31.10±1.46 to 45.60±2.92μm.Batches A1 and B1 containing 1%of aspirin had the highest EE of 70 and 72%respectively.Maximum in vitro release of 95.1 and 93.2%were obtained at 8 h from batches A1 and B1 respectively.SLMs exhibited about 77.8%oedema inhibition,while the reference had 66.7%and ulcer inhibition range of 25-75%.Aspirin-loaded SLMs exhibited good properties and could be used orally twice daily for the treatment of inflammation.展开更多
文摘The objectives of the work were to develop a lipid based delivery system for aspirin and to evaluate its physicochemical and pharmacodynamic properties.Aspirin-loaded solid lipid microparticles(SLMs)were formulated by hot homogenization and analysed for their encapsulation efficiency(EE%),in vitro release,particle size,anti-inflammatory and ulcer inhibition properties.Particle size ranged from 33.10±5.85 to 43.50±7.27μm for batches A1 to A3 SLMs loaded with 1,3 and 5%aspirin and containing Poloxamer 407,while batches B1,B2 and B3 formulated with Soluplus as surfactant had particle size range of 31.10±1.46 to 45.60±2.92μm.Batches A1 and B1 containing 1%of aspirin had the highest EE of 70 and 72%respectively.Maximum in vitro release of 95.1 and 93.2%were obtained at 8 h from batches A1 and B1 respectively.SLMs exhibited about 77.8%oedema inhibition,while the reference had 66.7%and ulcer inhibition range of 25-75%.Aspirin-loaded SLMs exhibited good properties and could be used orally twice daily for the treatment of inflammation.
